
    
      Patients selection criteria:

        -  age 18 - 70 years

        -  Women with cytologically or histologically proven metastatic breast cancer with
           recurrent / progressive brain metastases evaluable by MRI, after standard treatment with
           surgery (at least 3 weeks prior) or WBRT (at least 3 weeks prior) or stereotactic RT (at
           least 1 week prior); or otherwise deemed as unsuitable for standard treatment in the
           first instance

        -  Known HER-2 positive status (immunohistochemistry (IHC) 3+ Fluorescence In Situ
           Hybridization (FISH) positive )

        -  Previous chemotherapy (adjuvant and metastatic regimens) allowed

        -  Previous treatment with trastuzumab allowed (Trastuzumab to be discontinued prior to
           study entry)

        -  At least one measurable lesion in the brain, defined as any lesion >5mm in longest
           dimension on T1-weighted, gadolinium-enhanced MRI

        -  Expected life-expectancy of more than 3 months

        -  ECOG performance status of 0, 1 or 2

        -  Adequate bone marrow, renal and hepatic functionsLVEF

        -  LVEF 50% measured by echocardiography or MUGA scan

        -  Concomitant corticosteroids and anti-convulsants for symptomatic brain metastases are
           allowed
    
  